Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasm Metastasis 3Carcinoma 3Pancreatic Neoplasms 2Melanoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Fibrosarcoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Ifosfamide 4Doxorubicin 4Imatinib Mesylate 3Filgrastim 3brostallicin 2Vincristine 2Sunitinib 2Radiotherapy 2Radiation Dose Hypofractionation 2Etoposide 2Dactinomycin 2Cyclophosphamide 2Carboplatin 2temsirolimus 1soblidotin 1saracatinib 1romidepsin 1reolysin 1perifosine 1pazopanib 1exatecan 1etoposide phosphate 1cixutumumab 1Trabectedin 1Topotecan 1Thiotepa 1Temozolomide 1Surgical Procedures, Operative 1Sirolimus 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fibrosarcoma × reolysin × Clear all
NCT00503295 2014-10-02

Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung

Oncolytics Biotech

Phase 2 Completed
53 enrolled
Sarcoma

Fibrosarcoma, Leiomyosarcoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡